Luminist Labs

Luminist Labs discovered genuine demand for their liver fibrosis diagnostic through clinician behavior rather than surveys. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Hepatologists began requesting early access to their non-invasive test before commercial launch, signaling real clinical need—existing alternatives required invasive biopsies that patients avoided. The company measured interest by tracking adoption rates across partner hospitals, where usage grew 40% quarter-over-quarter as word spread among gastroenterology departments. Early traction appeared in their pilot programs with major medical centers, where physicians integrated the test into standard NASH screening protocols within weeks. The strongest validation came from insurance companies proactively requesting health economic data, indicating they anticipated high patient demand and wanted reimbursement frameworks ready. Additionally, Luminist observed repeat ordering patterns from the same clinicians, proving the test solved a persistent problem rather than satisfying curiosity. These behavioral signals—unsolicited adoption requests, rapid integration into clinical workflows, and insurer interest—demonstrated market pull that transcended stated interest, ultimately attracting DiscernDx's acquisition in 2020.